Real‐world glycaemic outcomes observed with the use of Medtronic 780G , Tandem Control‐ IQ and Omnipod 5 automated insulin delivery systems
Diabetic Medicine · 2026
DOI: 10.1111/dme.70251 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Diabetic Medicine, 2026. Verfasst von Muhammad S Khan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Imperial College School of Medicine, Imperial College London, London, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin Infusion Systems, Insulin, Hypoglycemic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
No randomised controlled trials have directly compared commercially available hybrid automated insulin delivery (AID) systems, and real‐world comparative data remain limited. This study evaluated glycaemic outcomes across three hybrid AID systems in adults with type 1 diabetes (T1D).
Methods
This was a retrospective, observational, single‐centre study and included adults with T1D who transitioned from multiple daily injections (MDI) or non‐automated insulin pump therapy to hybrid AID. Data were collected from routinely used clinical data‐sharing platforms and electronic health records. Outcomes compared across systems included time in range (TIR; 3.9–10.0 mmol/L), time below range (TBR; 13.9 mmol/L), glucose management indicator (GMI, %) and coefficient of variation (CV, %).
Results
A total of 213 participants were included (Medtronic 780G n = 38; Tandem Control‐IQ n = 81; Omnipod 5 n = 94). After adjustment for baseline TIR, diabetes duration, insulin modality and AID use duration 780G users achieved a higher TIR increase (21.1% [95% CI 18.4–23.7]) compared to Control‐IQ (10.1% [3.2–17.3], p = 0.010) and Omnipod 5 (15.2% [12.9–17.5], p = 0.002), with corresponding reductions in TAR.
Conclusion
All three hybrid AID systems were associated with improvements in glycaemic outcomes in real‐world use, supporting the role of AID systems in the management of T1D. Medtronic 780G use was associated with higher TIR increase compared with the other systems; however, these findings are based on measurements from different continuous glucose monitors between AID groups and cannot be used to infer superiority in glycaemic attainment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Imperial College School of Medicine, Imperial College London, London, UK.
- Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
- Imperial College Healthcare NHS Trust, London, UK.
- School of Medicine, Keele University, Keele, Staffordshire, UK.
ORCID-Profile: Ian Godsland, Monika Reddy
Zitieren
APA
Khan, M. S., Sivanantham, S., Farouk, L., Lakshmareddy, D. R., De Scolasticis, S., Cresta, E., Godsland, I., Avari, P., Oliver, N., Leelarathna, L., & Reddy, M. (2026). Real‐world glycaemic outcomes observed with the use of Medtronic 780G , Tandem Control‐ IQ and Omnipod 5 automated insulin delivery systems. Diabetic Medicine. https://doi.org/10.1111/dme.70251
Vancouver
Khan MS, Sivanantham S, Farouk L, Lakshmareddy DR, De Scolasticis S, Cresta E, et al. Real‐world glycaemic outcomes observed with the use of Medtronic 780G , Tandem Control‐ IQ and Omnipod 5 automated insulin delivery systems. Diabetic Medicine. 2026. doi:10.1111/dme.70251
BibTeX
@article{Khan2026,
author = {Khan, Muhammad S and Sivanantham, Sathana and Farouk, Lavanta and Lakshmareddy, Deeksha Reddy and De Scolasticis, Sara and Cresta, Elisabeth and Godsland, Ian and Avari, Parizad and Oliver, Nick and Leelarathna, Lalantha and Reddy, Monika},
title = {Real‐world glycaemic outcomes observed with the use of Medtronic 780G , Tandem Control‐ IQ and Omnipod 5 automated insulin delivery systems},
journal = {Diabetic Medicine},
year = {2026},
doi = {10.1111/dme.70251}
}
EUVIMED